UnipharDUB:UPR +0.42%81 3-Year ROIIC % is 7.55 as of Dec. 2025, which is 1% below its 10-year median of 7.62. GuruFocus rates DUB:UPR with a GF Score™ of 81/100 and a GF Value™ of €3.64 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 112 Medical Distribution companies, Uniphar ranks better than 66.96% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Uniphar's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 7.55%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Uniphar's 3-Year ROIIC % or its related term are showing as below:
DUB:UPR's 3-Year ROIIC % is ranked better than 66.96% of 112
companies
in the Medical Distribution industry
Industry Median: 2.145
vs DUB:UPR: 7.55
Uniphar (DUB:UPR) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Uniphar 3-Year ROIIC % Related Terms
Uniphar 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Uniphar's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DUB:UPR vs MCK, CAH, COR: 3-Year ROIIC % Comparison
For the Medical Distribution subindustry, Uniphar's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Uniphar's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Uniphar (DUB:UPR) has a 3-Year ROIIC % of 7.55 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Uniphar and its competitors. This is near median its historical median of 7.62. Over the past decade, Uniphar's 3-Year ROIIC % has ranged from 5.34 to 9.66. According to the industry distribution chart, Uniphar ranks #37 out of 112 companies in the Medical Distribution industry, placing it in the top 33%.
Is Uniphar's 3-Year ROIIC % too high?
Uniphar's current 3-Year ROIIC % of 7.55 is near median its 10-year median of 7.62. Over the past 10 years, this metric has ranged from a low of 5.34 to a high of 9.66. The Medical Distribution industry median 3-Year ROIIC % is 2.15. Uniphar's value of 7.55 is 252% above this industry median. Based on the distribution chart, Uniphar ranks #37 out of 112 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Uniphar has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's 3-Year ROIIC % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Uniphar ranks #37 out of 112 companies for 3-Year ROIIC %. This puts Uniphar in the upper half of its industry. The industry median 3-Year ROIIC % is 2.15. Uniphar's value of 7.55 is 252% above this benchmark. Historically, Uniphar's own 3-Year ROIIC % has ranged from 5.34 to 9.66 over the past decade. While the company's 10-year median is 7.62 vs. the industry median of 2.15, Uniphar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.15, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current 3-Year ROIIC % of 7.55 is 252% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current 3-Year ROIIC % is 7.55, which is near median its own 10-year median of 7.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.82 — trading 32.4% above its estimated fair value. The current 3-Year ROIIC % is 7.55, which is near median its 10-year median of 7.62 and 252% above the Medical Distribution industry median of 2.15. Uniphar's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current 3-Year ROIIC % is 7.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.82 is trading 32.4% above its estimated GF Value™ of €3.64.
GuruFocus considers Uniphar to be Significantly Overvalued.
Key valuation signals for DUB:UPR:
3-Year ROIIC %: 7.55 (near median its 10-year median of 7.62)
GF Value™: €3.64 vs. price of €4.82 (32.4% above fair value)
Industry Position: 252% above the Medical Distribution median (#37 of 112)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
81GF Score
Get the complete analysis for DUB:UPR
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
